Physicians' Academy for Cardiovascular Education

PCSK9i: Benefits across the spectrum of cardiovascular disease

10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD - Amsterdam, The Netherlands

Video navigation menu

  • CV-risk reduction with PCSK9i 01:43
  • The higher the CV risk, the more benefit 04:21
  • Conclusions and take home messages 08:02


Show transcript

Educational information

This lecture by Fabrice Martens, MD, PhD was part of the EBAC-accredited symposium "The LDL-c challenge in high cardiovascular risk: Integrating innovative therapies in clinical management" held during the ESC congress 2023.


Prof. Fabrice Martens, MD, PhD is a cardiologist and full professor Preventive Cardiology at the Amsterdam UMC in The Netherlands.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Amgen, NewAmsterdam Pharma, Sanofi and Viatris.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: